Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

医学 内科学 彭布罗利珠单抗 肿瘤科 结直肠癌 生活质量(医疗保健) 癌症 DNA错配修复 打开标签 微卫星不稳定性 化疗 随机对照试验 生物 护理部 等位基因 基因 免疫疗法 微卫星 生物化学
作者
Thierry André,Mayur M. Amonkar,Josephine M. Norquist,K-K. Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J.A. Punt,Denis Smith,Rocio García‐Carbonero,Isabel Sevilla,Christelle De La Fouchardière,Fernando Rivera,Elena Élez,Luis A. Díaz,Takayuki Yoshino,Eric Van Cutsem,Ping Yang,Mohammed Z.H. Farooqui,Dung T. Le
出处
期刊:Lancet Oncology [Elsevier]
卷期号:22 (5): 665-677 被引量:140
标识
DOI:10.1016/s1470-2045(21)00064-4
摘要

In the KEYNOTE-177 study, pembrolizumab monotherapy provided statistically significant and clinically meaningful improvements in progression-free survival versus chemotherapy as first-line treatment in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. To further support the efficacy and safety findings of the KEYNOTE-177 study, results of the health-related quality of life (HRQOL) analyses are reported here.KEYNOTE-177 is an open-label, randomised, phase 3 trial being done at 192 cancer centres in 23 countries, in patients aged 18 years and older with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and who had not received previous systemic therapy for metastatic disease. Eligible patients were randomly assigned (1:1) centrally by use of interactive voice response or integrated web response technology to receive pembrolizumab 200 mg intravenously every 3 weeks or investigator's choice chemotherapy (mFOLFOX6 [leucovorin, fluorouracil, and oxaliplatin] or FOLFIRI [leucovorin, fluorouracil, and irinotecan] intravenously every 2 weeks with or without intravenous bevacizumab or cetuximab). Patients and investigators were not masked to treatment assignment. The primary endpoints were progression-free survival (previously reported) and overall survival (data to be reported at the time of the final analysis). HRQOL outcomes were evaluated as prespecified exploratory endpoints. The analysis population comprised all randomly assigned patients who received at least one dose of study treatment and completed at least one HRQOL assessment. HRQOL outcomes were mean change from baseline to prespecified week 18 in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Quality of Life Questionnaire-Colorectal 29 (EORTC QLQ-CR29) scale and item scores, and in the EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L) visual analogue scale and health utility scores; the proportion of patients with improved, stable, or deteriorated scores from baseline to prespecified week 18 in EORTC QLQ-C30 scales and items; and time to deterioration in EORTC QLQ-C30 global health status/quality of life (GHS/QOL), physical functioning, social functioning, and fatigue scores and EORTC QLQ-CR29 urinary incontinence scores. The threshold for a small and clinically meaningful mean difference in EORTC QLQ-C30 score was 5-8 points. This study is registered with ClinicalTrials.gov, NCT02563002 and is ongoing; recruitment is closed.Between Feb 11, 2016, and Feb 19, 2018, 307 patients were enrolled and randomly assigned to receive pembrolizumab (n=153) or chemotherapy (n=154). The HRQOL analysis population comprised 294 patients (152 receiving pembrolizumab and 142 receiving chemotherapy). As of Feb 19, 2020, median time from randomisation to data cutoff was 32·4 months (IQR 27·7-37·8). Least squares mean (LSM) change from baseline to prespecified week 18 showed a clinically meaningful improvement in EORTC QLQ-C30 GHS/QOL scores with pembrolizumab versus chemotherapy (between-group LSM difference 8·96 [95% CI 4·24-13·69]; two-sided nominal p=0·0002). Median time to deterioration was longer with pembrolizumab versus chemotherapy for GHS/QOL (hazard ratio 0·61 [95% CI 0·38-0·98]; one-sided nominal p=0·019), physical functioning (0·50 [95% CI 0·32-0·81]; one-sided nominal p=0·0016), social functioning (0·53 [95% CI 0·32-0·87]; one-sided nominal p=0·0050), and fatigue scores (0·48 [95% CI 0·33-0·69]; one-sided nominal p<0·0001).Pembrolizumab monotherapy led to clinically meaningful improvements in HRQOL compared with chemotherapy in patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. These data, along with the previously reported clinical benefits, support pembrolizumab as a first-line treatment option for this population.Merck Sharp & Dohme, a subsidiary of Merck & Co, Kenilworth, NJ, USA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
3秒前
4秒前
冲冲发布了新的文献求助10
5秒前
稳如老狗发布了新的文献求助10
6秒前
我要发文章完成签到 ,获得积分10
6秒前
小飞飞发布了新的文献求助10
8秒前
田様应助zwz采纳,获得10
9秒前
11秒前
丹霞完成签到,获得积分10
12秒前
脑洞疼应助小飞飞采纳,获得10
13秒前
DrZ发布了新的文献求助10
15秒前
16秒前
FashionBoy应助hu采纳,获得10
16秒前
17秒前
19秒前
BMII发布了新的文献求助10
19秒前
不知名的呆毛完成签到,获得积分10
19秒前
19秒前
SciGPT应助万刈采纳,获得10
19秒前
小蘑菇应助小七采纳,获得10
21秒前
文献完成签到,获得积分10
21秒前
22秒前
22秒前
22秒前
zh发布了新的文献求助10
23秒前
树夏发布了新的文献求助10
24秒前
24秒前
WeiBao发布了新的文献求助10
24秒前
27秒前
上官若男应助你好采纳,获得10
27秒前
思源应助vantie采纳,获得10
28秒前
Lll发布了新的文献求助10
31秒前
云游的莫冷完成签到,获得积分20
32秒前
伟蓓1314发布了新的文献求助10
32秒前
34秒前
35秒前
36秒前
37秒前
乌拉乌拉发布了新的文献求助20
38秒前
高分求助中
Sustainability in Tides Chemistry 2000
The ACS Guide to Scholarly Communication 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Gerard de Lairesse : an artist between stage and studio 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3076078
求助须知:如何正确求助?哪些是违规求助? 2729019
关于积分的说明 7507089
捐赠科研通 2377245
什么是DOI,文献DOI怎么找? 1260517
科研通“疑难数据库(出版商)”最低求助积分说明 610983
版权声明 597164